Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246

NCT03268382 is registered in ClinicalTrials.gov with Aprea Therapeutics as lead sponsor.

NCT NCT03268382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03268382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246
Lead sponsor
Aprea Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2017
Completion date
July 10, 2019
Enrollment
36 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade serous ovarian cancer